HS
LXRX icon

HighVista Strategies’s Lexicon Pharmaceuticals LXRX Stock Holding History

HighVista Strategies’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,978
Closed -$135K – 95
2021
Q3 		$135K Buy
27,978
+11,935
+74% +$49K 0.09% 81
2021
Q2 		$74K Buy
+16,043
New +$77.3K 0.05% 108

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighVista Strategies's LXRX Position: Q4 2021 in Review

HighVista Strategies sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2021, closing a stake of 27,978 shares — an estimated $135K sold.

HighVista Strategies first reported a position in LXRX in Q2 2021 and held it in 2 quarters. The position peaked at $135K in Q3 2021. 110 funds tracked by Wall St. Rank hold LXRX as of Q4 2021.

  • HighVista Strategies reported no remaining Lexicon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • HighVista Strategies sold 27,978 Lexicon Pharmaceuticals shares in Q4 2021, an estimated $135K.
  • HighVista Strategies first reported a position in Lexicon Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • HighVista Strategies's Lexicon Pharmaceuticals position peaked at $135K in Q3 2021.
  • 110 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.